Colorectal cancer (CRC) has been a major public health problem. Tumor microenvironment (TME) greatly contributes to the heterogeneity of CRC and is crucial for the regulation of CRC progression. The authors' study aimed to develop a robust prognostic signature for CRC patients based on TME-related genes.
Materials and Methods:
Gene expression data and clinicopathologic information of CRC patients were collected from Gene Expression Omnibus and The Cancer Genome Atlas databases. TME-related genes with prognostic value were identified by Cox regression and bootstrap method. The authors used the prognostic genes to construct a robust prognostic model using the least absolute shrinkage and selection operator (LASSO) regression method. The immune and stromal cell abundance of CRC samples were estimated by a microenvironment cell populations-counter method.
Results:
Based on a training set that comprised 893 CRC samples and 4775 TME-related genes, they established a prognostic model consisting of 25 TME-related genes. With specific risk score formulae, the prognostic model divided CRC patients into high-risk and low-risk subgroups with significantly different survival, which were further confirmed in validation cohorts consisting of other 473 CRC cases or subpopulation of specific stages. The result of time-dependent receiver operating characteristic analysis demonstrated strong predictive accuracy of the prognostic model both in training and validation cohorts. Multivariate Cox regression analysis showed that the 25-gene signature was an independent prognostic factor for overall survival, which was validated through clinical subgroups analysis. Further analysis revealed that CRC samples of high-risk group was abundant of stromal-relevant processes and had a significantly higher proportion of fibroblasts and endothelial cells infiltration.
Conclusion:
The authors established a robust prognostic signature of 25 TME-related genes which may be an effective tool for prognostic prediction and CRC patient stratification to assist in making treatment decisions.
Get full access to this article
View all access options for this article.
References
1.
BrayF, FerlayJ, SoerjomataramI, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018; 68:394.
2.
JemalA, BrayF, CenterMM, et al.Global cancer statistics. CA Cancer J Clin, 2011; 61:69.
3.
PuntCJA, KoopmanM, VermeulenL. From tumour heterogeneity to advances in precision treatment of colorectal cancer. Nat Rev Clin Oncol, 2017; 14:235.
4.
QuailDF, JoyceJA. Microenvironmental regulation of tumor progression and metastasis. Nat Med, 2013; 19:1423.
5.
LeDT, DurhamJN, SmithKN, et al.Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science, 2017; 357:409.
6.
GaneshK, StadlerZK, CercekA, et al.Immunotherapy in colorectal cancer: Rationale, challenges and potential. Nat Rev Gastroenterol Hepatol, 2019; 16:361.
7.
GalonJ. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science, 2006; 313:1960.
8.
PagèsF, MlecnikB, MarliotF, et al.International validation of the consensus Immunoscore for the classification of colon cancer: A prognostic and accuracy study. Lancet, 2018; 391:2128.
9.
TsujinoT, SeshimoI, YamamotoH, et al.Stromal myofibroblasts predict disease recurrence for colorectal cancer. Clin Cancer Res, 2007; 13:2082.
10.
HenryLR, LeeHO, LeeJS, et al.Clinical implications of fibroblast activation protein in patients with colon cancer. Clin Cancer Res, 2007; 13:1736.
11.
YamanashiT, NakanishiY, FujiiG, et al.Podoplanin expression identified in stromal fibroblasts as a favorable prognostic marker in patients with colorectal carcinoma. Oncology, 2009; 77:53.
12.
Abdul AzizNA, MokhtarNM, HarunR, et al.A 19-Gene expression signature as a predictor of survival in colorectal cancer. BMC Med Genomics, 2016; 9:58.
13.
LiM, WangH, LiW, et al.Identification and validation of an immune prognostic signature in colorectal cancer. Int Immunopharmacol, 2020; 88:106868.
14.
WuJ, ZhaoY, ZhangJ, et al.Development and validation of an immune-related gene pairs signature in colorectal cancer. Oncoimmunology, 2019; 8:1596715.
15.
XiongY, WangK, ZhouH, et al.Profiles of immune infiltration in colorectal cancer and their clinical significant: A gene expression-based study. Cancer Med, 2018; 7:4496.
16.
FakihM, OuyangC, WangC, et al.Immune overdrive signature in colorectal tumor subset predicts poor clinical outcome. J Clin Invest, 2019; 129:4464.
17.
FridmanWH, MillerI, Sautès-FridmanC, ByrneAT. Therapeutic targeting of the colorectal tumor stroma. Gastroenterology, 2020; 158:303.
18.
KobayashiH, GieniecKA, WrightJA, et al.The balance of stromal BMP signaling mediated by GREM1 and ISLR drives colorectal carcinogenesis. Gastroenterology, 2021; 160:1224.
19.
PapeJ, MagdeldinT, StamatiK, et al.Cancer-associated fibroblasts mediate cancer progression and remodel the tumouroid stroma. Br J Cancer, 2020; 123:1178.
20.
UnterleuthnerD, NeuholdP, SchwarzK, et al.Cancer-associated fibroblast-derived WNT2 increases tumor angiogenesis in colon cancer. Angiogenesis, 2020; 23:159.
21.
GautierL, CopeL, BolstadBM, IrizarryRA. Affy–Analysis of Affymetrix GeneChip data at the probe level. Bioinformatics, 2004; 20:307.
22.
LeekJT, JohnsonWE, ParkerHS, et al.The SVA package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics, 2012; 28:882.
BechtE, GiraldoNA, LacroixL, et al.Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol, 2016; 17:218.
25.
BindeaG, MlecnikB, TosoliniM, et al.Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity, 2013; 39:782.
26.
CharoentongP, FinotelloF, AngelovaM, et al.Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep, 2017; 18:248.
27.
ClancyT, HovigE. Profiling networks of distinct immune-cells in tumors. BMC Bioinformatics, 2016; 17:263.
28.
NewmanAM, LiuCL, GreenMR, et al.Robust enumeration of cell subsets from tissue expression profiles. Nat Methods, 2015; 12:453.
29.
RacleJ, de JongeK, BaumgaertnerP, et al.Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data. eLife, 2017; 13;6:e26476.
30.
RooneyMS, ShuklaSA, WuCJ, et al.Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell, 2015; 160:48.
31.
TiroshI, IzarB, PrakadanSM, et al.Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science, 2016; 352:189.
32.
YoshiharaK, ShahmoradgoliM, MartínezE, et al.Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun, 2013; 4:2612.
33.
WilkersonMD, HayesDN. ConsensusClusterPlus: A class discovery tool with confidence assessments and item tracking. Bioinformatics, 2010; 26:1572.
34.
ChenY, ZhaoJ. Identification of an immune gene signature based on tumor microenvironment characteristics in colon adenocarcinoma. Cell Transplant, 2021; 30:9636897211001314.
35.
CaiQ, HeB, XieH, et al.Identification of a novel prognostic DNA methylation signature for lung adenocarcinoma based on consensus clustering method. Cancer Med, 2020; 9:7488.
36.
TangC, MaJ, LiuX, LiuZ. Identification of four immune subtypes in bladder cancer based on immune gene sets. Front Oncol, 2020; 10:544610.
37.
SonpatkiP, ShahN. Recursive Consensus Clustering for novel subtype discovery from transcriptome data. Sci Rep, 2020; 10:11005.
38.
ZhangC, ZhangZ, ZhangG, et al.Clinical significance and inflammatory landscapes of a novel recurrence-associated immune signature in early-stage lung adenocarcinoma. Cancer Lett, 2020; 479:31.
39.
LiJ, LiX, ZhangC, et al.A signature of tumor immune microenvironment genes associated with the prognosis of non-small cell lung cancer. Oncol Rep, 2020; 43:795.
40.
MiaoY, LiQ, WangJ, et al.Prognostic implications of metabolism-associated gene signatures in colorectal cancer. PeerJ, 2020; 8:e9847.
41.
WuM, LiX, ZhangT, et al.Identification of a nine-gene signature and establishment of a prognostic nomogram predicting overall survival of pancreatic cancer. Front Oncol, 2019; 9:996.
WuW, XuW, SunW, et al.Forced vital capacity predicts the survival of interstitial lung disease in anti-MDA5 positive dermatomyositis: A multi-centre cohort study. Rheumatology, 2021. [Epub ahead of print]; DOI: 10.1093/rheumatology/keab305.
44.
LiS, ChenS, WangB, et al.A robust 6-lncRNA prognostic signature for predicting the prognosis of patients with colorectal cancer metastasis. Front Med, 2020; 7:56.
45.
TangY, YangX, FengK, et al.High expression of aldolase A is associated with tumor progression and poor prognosis in hepatocellular carcinoma. J Gastrointest Oncol, 2021; 12:174.
46.
WangB, ZhangY. An immune-relevant signature of nine genes as a prognostic biomarker in patients with gastric carcinoma. Open Med, 2020; 15:850.
47.
HeagertyPJ, LumleyT, PepeMS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics, 2000; 56:337.
48.
ZhuX, TianX, JiL, et al.A tumor microenvironment-specific gene expression signature predicts chemotherapy resistance in colorectal cancer patients. NPJ Precis Oncol, 2021; 5:7.
49.
CaoB, WangQ, ZhangH, et al.Two immune-enhanced molecular subtypes differ in inflammation, checkpoint signaling and outcome of advanced head and neck squamous cell carcinoma. Oncoimmunology, 2017; 7:e1392427.
50.
YuG, WangLG, HanY, HeQY. ClusterProfiler: An R package for comparing biological themes among gene clusters. OMICS, 2012; 16:284.
51.
TeichertM, MildeL, HolmA, et al.Pericyte-expressed Tie2 controls angiogenesis and vessel maturation. Nat Commun, 2017; 8:16106.
52.
RochetteA, BoufaiedN, ScarlataE, et al.Asporin is a stromally expressed marker associated with prostate cancer progression. Br J Cancer, 2017; 116:775.
53.
ChallaAA, StefanovicB. A novel role of vimentin filaments: Binding and stabilization of collagen mRNAs. Mol Cell Biol, 2011; 31:3773.
54.
VogtL, SchmitzN, KurrerMO, et al.VSIG4, a B7 family-related protein, is a negative regulator of T cell activation. J Clin Invest, 2006; 116:2817.
55.
EtzerodtA, TsalkitziK, ManieckiM, et al.Specific targeting of CD163+ TAMs mobilizes inflammatory monocytes and promotes T cell-mediated tumor regression. J Exp Med, 2019; 216:2394.
56.
GeorgoudakiAM, ProkopecKE, BouraVF, et al.Reprogramming tumor-associated macrophages by antibody targeting inhibits cancer progression and metastasis. Cell Rep, 2019; 216:2394.
57.
FridmanWH, PagèsF, Saut̀s-FridmanC, GalonJ. The immune contexture in human tumours: Impact on clinical outcome. Nat Rev Cancer, 2012; 12:298.
58.
TorresS, BartoloméRA, MendesM, et al.Proteome profiling of cancer-associated fibroblasts identifies novel proinflammatory signatures and prognostic markers for colorectal cancer. Clin Cancer Res, 2013; 19:6006.
59.
PagèsF, KirilovskyA, MlecnikB, et al.In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol, 2009; 27:5944.
60.
ZhuL, WangH, WangZ. A five-immune-related genes-based prognostic signature for colorectal cancer. Int Immunopharmacol, 2020; 88:106866.
61.
GuinneyJ, DienstmannR, WangX, et al.The consensus molecular subtypes of colorectal cancer. Nat Med, 2015; 21:1350.
62.
CalonA, LonardoE, Berenguer-LlergoA, et al.Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat Genet, 2015; 47:320.
63.
UenoH, KanemitsuY, SekineS, et al.Desmoplastic pattern at the tumor front defines poor-prognosis subtypes of colorectal cancer. Am J Surg Pathol, 2017; 41:1506.
64.
Gonçalves-RibeiroS, Sanz-PamplonaR, VidalA, et al.Prediction of pathological response to neoadjuvant treatment in rectal cancer with a two-protein immunohistochemical score derived from stromal gene-profiling. Ann Oncol, 2017; 28:2160.
65.
WangZ, TangY, TanY, et al.Cancer-associated fibroblasts in radiotherapy: Challenges and new opportunities. Cell Commun Signal, 2019; 17:47.
66.
TaurielloDVF, Palomo-PonceS, StorkD, et al.TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis. Nature, 2018; 554:538.
67.
WalkerC, MojaresE, Del Río HernándezA. Role of extracellular matrix in development and cancer progression. Int J Mol Sci, 2018; 19:3028.
68.
ViallardC, LarrivéeB. Tumor angiogenesis and vascular normalization: Alternative therapeutic targets. Angiogenesis, 2017; 20:409.
69.
KalluriR. The biology and function of fibroblasts in cancer. Nat Rev Cancer, 2016; 16:582.
ThommenDS, SchumacherTN. T cell dysfunction in cancer. Cancer Cell, 2018; 33:547.
72.
O'MalleyG, TreacyO, LynchK, et al.Stromal cell PD-L1 inhibits CD8+ T-cell antitumor immune responses and promotes colon cancer. Cancer Immunol Res, 2018; 6:1426.
73.
SinicropeFA, RegoRL, HallingKC, et al.Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients. Gastroenterology, 2006; 131:729.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
